A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma-Reference-Cited by-同舟云学术

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma

Published:2014-08-07 Issue:6 Volume:124 Page:899-906
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Lendvai Nikoletta¹²,Hilden Patrick³,Devlin Sean³,Landau Heather²⁴,Hassoun Hani¹²,Lesokhin Alexander M.¹²,Tsakos Ioanna⁵,Redling Kaitlyn⁵,Koehne Guenther²⁴,Chung David J.²⁴,Schaffer Wendy L.²⁶,Giralt Sergio A.²⁴

Affiliation:

1. Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, NY;

2. Department of Medicine, Weill Medical College of Cornell University, New York, NY; and

3. Epidemiology and Biostatistics,

4. Adult Bone Marrow Transplantation Service,

5. Department of Medicine, and

6. Cardiology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

Abstract

Key Points Carfilzomib 56 mg/m2 provided a high overall response rate with a remarkable duration of response in patients with R/RMM. Nonhematologic grade 3/4 AEs likely related to carfilzomib treatment included hypertension and heart failure.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/6/899/1381762/899.pdf

Reference31 articles.

1. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.;Demo;Cancer Res,2007

2. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.;Kuhn;Blood,2007

3. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.;Parlati;Blood,2009

4. Molecular mechanisms of bortezomib resistant adenocarcinoma cells.;Suzuki;PLoS ONE,2011

5. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.;Siegel;Blood,2012

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rediscovering hemostasis abnormalities in multiple myeloma: The new era;Heliyon;2024-07

2. Development of Proteasome Inhibitors for Cancer Therapy;International Journal of Drug Discovery and Pharmacology;2024-03-18

3. Management of Relapsed and Refractory Multiple Myeloma: Recent advances;Indian Journal of Medical and Paediatric Oncology;2022-11-29

4. Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls;Journal of Clinical Medicine;2022-06-10

5. Optimised point estimators for multi-stage single-arm phase II oncology trials;Journal of Biopharmaceutical Statistics;2022-02-23